Articles related to CONTRACEPTION/BIRTH CONTROL

Maternal immunization with 2 doses of vaccine was 97% and 53% effective against infant hospitalization from delta and omicron variants, respectively. The effectiveness of the vaccine in preventing infant hospitalization declined by nearly 20% after 16 weeks. Receiving the second dose in the third trimester yielded the greatest benefit.

Emzahh (norethindrone tablets), the progestin-only generic equivalent of the discontinued Ortho Micronor, was approved via an abbreviated NDA.

Although research exists on the impact of CNS stimulants used in pregnancy, only a few small studies have looked at atomoxetine and pregnancy outcomes. This large cohort study of 4.2 million pregnancies ending in live births in northern Europe and the US reviewed nearly 1,000 pregnancies exposed to atomoxetine in the first trimester. Compared with non-exposed pregnancies, there was no observed increase in major congenital abnormalities with atomoxetine use in the first trimester.

Today, it is possible to safely treat CML throughout pregnancy with little danger to the unborn child, as TKIs can now be safely administered during the later stages of pregnancy, according to new research. After beginning or continuing TKI therapy, a sizable majority of patients can be managed by observation alone, and disease control can be attained. IFN-α may be given in any trimester with little harm to the fetus if active treatment is necessary. Most essential, however, is a multidisciplinary strategy to offer clear and concise guidance to enable both the mother and the family to participate in the decision-making process.

During pregnancy and the postpartum period, the body is subjected to abnormal stress, raising the possibility of eye and vision-related conditions and complications. Refractive changes, central serous chorioretinopathy, Purtscher-like retinopathy, diabetes, hypertension, and immunologic diseases are examples of eye and vision-related conditions and complications. Although diabetic retinopathy that develops during pregnancy usually resolves on its own after delivery, women are still at risk of progression for up to a year after delivery.

Pregnant women who filled prescriptions for bupropion, citalopram, escitalopram, fluoxetine, or sertraline during pregnancy (antidepressant-exposed cohort) and pregnant women who did not fill an antidepressant prescription within 90 days of the start of their pregnancy through delivery (control group) were the subjects of the study conducted by researchers from Brigham and Women’s Hospital in the United States. The main finding concerned the frequency of ADHD, autism spectrum disorder (ASD), behavioral disorder, developmental coordination disorder, developmental speech or language disorder, intellectual disability, any NDDs, and specific learning disorders among the children of the women in the study.